Tim Miller is Head of Business Development at HiFiBiO Therapeutics, where he leads global partnering strategy to advance the company’s biotherapeutic pipeline. He brings more than a decade of experience spanning business development, alliance management, and contracting within the life sciences and biotechnology sectors.

Prior to HiFiBiO, Tim served as Director of Business Development at MindWalk (formerly IPA), where he led global licensing and strategic partnerships across five international operating sites. In parallel, he oversaw the company’s global contracting and  Prior to MindWalk, Tim worked at Harbour BioMed, where he focused on technology licensing and alliance management, with particular emphasis on the company’s proprietary transgenic animal platforms supporting antibody discovery and therapeutic development.

Tim holds a Master’s degree in International Infectious Disease Management and Biosecurity and a Bachelor’s degree in Microbiology, both from North Dakota State University.

Alexandre Grassin is Senior Vice President, Head of Finance at HiFiBiO Therapeutics. He is a seasoned biotech finance executive with over 25 years of international experience across the U.S. and Europe, spanning both private and public companies.

Alex has supported multiple equity and debt financings and played a central role in bringing companies to the public markets on Euronext and Nasdaq through reverse takeovers (RTO) and SPAC transactions, as well as in M&A exits. At HiFiBiO, he oversees global finance and accounting and works closely with the executive team to support strategic planning, financial discipline, and long-term value creation.

Prior to HiFiBiO, Alex served as CFO or interim CFO for several biotech and medtech companies, including Genkyotex, Aleva Neurotherapeutics, and enGene, and held senior finance roles at Alexion and Novartis. He began his career at KPMG in audit.

Alex holds a degree in International Management and is based in Boston.

Yun-Yueh Lu is the Head of Research, Head of China Operations at HiFiBiO Therapeutics. She is a biologist with 10 years of biopharma industry experience. She currently oversees all aspects of preclinical research activities, along with managing general operational responsibilities in China.

Prior to joining HiFiBiO Therapeutics, she was part of the team at Sanofi, where she contributed to the discovery of small molecule therapies targeting viral diseases.

Yun-Yueh holds a Ph.D. in Infection Biology from Basel University in Switzerland, a M.Sc. in Virology from Wageningen University in the Netherland, and a B.Sc . from National Chung-Hsing University in Taiwan.

Melissa Harney is the Head of Clinical Operations & Regulatory Affairs at HiFiBiO Therapeutics, where she leads global clinical execution and regulatory strategy across the company’s Immunology & Inflammation and Immuno-Oncology programs. She brings over 20 years of experience in clinical development, regulatory oversight, and global trial operations within the biotech and pharmaceutical sectors.

Prior to joining HiFiBiO, Melissa held senior clinical operations leadership roles at Seven and Eight Biopharmaceuticals and supported global development programs at Advaxis, Daiichi Sankyo, and Pearl Therapeutics (acquired by AstraZeneca). She has overseen clinical and regulatory activities supporting both in-licensing and out-licensing transactions, including programs advanced through strategic partnerships with Eikon Therapeutics and AstraZeneca.

Melissa holds a Bachelor of Science degree in Clinical Psychology and an Associate degree in Healthcare Science, and completed professional certification programs through Association of Clinical Research Professionals (ACRP).